Dihydroergotamine has 24 known drug interactions based on U.S. FDA drug labeling data. Of these, 17 are contraindicated combinations that should be avoided entirely. 3 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Almotriptan, Almotriptan Malate, Eletriptan Hydrobromide. Patients taking Dihydroergotamine should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 24
- Contraindicated
- 17
- Major
- 3
- Moderate
- 4
Contraindicated (17)
- Dihydroergotamine + Almotriptan— Do not use within 24 hours of almotriptan due to risk of prolonged vasospastic reactions.
- Dihydroergotamine + Almotriptan Malate— Do not use almotriptan malate and dihydroergotamine within 24 hours of each other due to risk of prolonged vasospastic r…
- Dihydroergotamine + Eletriptan Hydrobromide— Ergot-containing drugs cause prolonged vasospastic reactions. Use within 24 hours of eletriptan hydrobromide is contrain…
- Dihydroergotamine + Erythromycin— Co-administration associated with acute ergot toxicity characterized by vasospasm and ischemia of extremities and other …
- Dihydroergotamine + Erythromycin Ethylsuccinate— Coadministration associated with acute ergot toxicity characterized by vasospasm and ischemia of extremities and central…
- Dihydroergotamine + Erythromycin Lactobionate— Co-administration associated with acute ergot toxicity characterized by vasospasm and ischemia of central nervous system…
- Dihydroergotamine + Frovatriptan Succinate— Ergot-type medication causing prolonged vasospastic reactions with additive effects to frovatriptan. Use within 24 hours…
- Dihydroergotamine + Itraconazole— Coadministration is contraindicated. Itraconazole increases plasma concentrations of ergot alkaloids, potentially increa…
- Dihydroergotamine + Ketoconazole— Coadministration of ketoconazole with dihydroergotamine is contraindicated.
- Dihydroergotamine + Mifepristone— Mifepristone increases dihydroergotamine exposure; concomitant use is contraindicated due to narrow therapeutic range.
- Dihydroergotamine + Naratriptan— Ergot-type medication causing prolonged vasospastic reactions with additive effects when used with naratriptan. Contrain…
- Dihydroergotamine + Rizatriptan— Dihydroergotamine causes prolonged vasospastic reactions with additive effects. Use within 24 hours is contraindicated.
- Dihydroergotamine + Rizatriptan Benzoate— Ergot-type medication causing prolonged vasospastic reactions. Use within 24 hours of rizatriptan benzoate is contraindi…
- Dihydroergotamine + Sumatriptan— Ergot-type medication causing prolonged vasospastic reactions with additive effects. Use within 24 hours of sumatriptan …
- Dihydroergotamine + Sumatriptan Succinate— Ergot-type medication causing prolonged vasospastic reactions; additive effects contraindicate use within 24 hours of su…
- Dihydroergotamine + Sumatriptan Succinate And Naproxen Sodium— Ergot-type medication causing prolonged vasospastic reactions. Coadministration within 24 hours is contraindicated due t…
- Dihydroergotamine + Zolmitriptan— Ergot-type medication causing prolonged vasospastic reactions. Use within 24 hours of zolmitriptan is contraindicated.
Major (3)
- Dihydroergotamine + Azithromycin— Macrolide products have been observed to cause acute ergot toxicity characterized by severe peripheral vasospasm and dys…
- Dihydroergotamine + Midodrine Hydrochloride— Increases risk of hypertension when used concomitantly with midodrine. Avoid concomitant use or monitor blood pressure c…
- Dihydroergotamine + Nitroglycerin— Oral nitroglycerin markedly decreases first-pass metabolism and increases bioavailability of dihydroergotamine; monitor …
Moderate (4)
- Dihydroergotamine + Deferasirox— Deferasirox may induce CYP3A4 resulting in decreased dihydroergotamine concentration. Monitor for reduced effectiveness.
- Dihydroergotamine + Methenamine, Sodium Phosphate, Monobasic, Monohydrate, Phenyl Salicylate, Methylene Blue, And Hyoscyamine Sulfate— Methylene blue inhibits CYP3A4/5 metabolism. Dihydroergotamine has narrow therapeutic index; clinical relevance unknown …
- Dihydroergotamine + Nitroglycerin Lingual— Oral nitroglycerin markedly decreases first-pass metabolism and increases oral bioavailability. Related to ergotamine; m…
- Dihydroergotamine + Palbociclib— Sensitive CYP3A substrate with narrow therapeutic index. Dose may need reduction when coadministered with palbociclib.